Boston, MA 10/18/2013 (wallstreetpr) – A drug tofacitinib which the drug maker Pfizer Inc. (NYSE:PFE) had earlier come up with to treat psoriasis is now seen to demonstrate mixed results in the trials. The company reported that the drug has shown non-inferiority compared to Enbrel in treating psoriasis in adults who were suffering moderately or severely from the disease, but only when patients are induced with high doses of the drug. The results were significant at a late stage study. However, contrasting results were seen when the patients were treated with lesser doses of the drug tofacitinib. Tofacitinib did not meet the non-inferiority criteria to high-dose Enbrel at the 5 mg BID dose.
The drug maker had carried out a 12 week study which they had named OPT Compare. Reportedly, more than around 7 million people are suffering from this disease in America. In the study, they administered 5mg and 10mg of the drug to patients two times every day. The drug was given orally and compared against placebo. At the same time, they also observed the results of the approved injectable drug Enbrel as per the established norm of starting dose of two doses per week. The effectiveness in both the cases was then observed.
An analyst of the SI Group concluded that the 10mg dose of the drug tofacitinib produces results of similar effectiveness as those produced by Enbrel, only the latter are high cost biotech drugs which are grown inside living cells. The restriction of the 10mg tofacitinib that he noted was the increased risk factor due to high doses over the 5mg dose of the drug, which in turn is less effective.